New England Journal Of Medicine Publishes Phase 2 Study Of VX-770 As A New Approach To Treat The Underlying Cause Of Cystic Fibrosis

 Cystic Fibrosis

VX-770 
Enhanced by Zemanta

No comments:

Post a Comment